Endo News Roundup: Diabetes Biomarker

Slideshow

March news includes a possible biomarker for diabetes, a new sensor to read glucose levels, and a study on insulin resistance and bone fracture.

New studies in diabetes include: an alternative sensor-based method for glucose monitoring in children and young people with type 1 diabetes (T1DM) appears to be accurate and safe; insulin resistance is associated with lower bone turnover levels, which could be a factor in the higher fracture rates seen in diabetes; and serum fibroblast growth factor 21 (FGF21) appears to be a good biomarker for diabetes prediction, and could be considered as an alternative to the oral glucose tolerance test (OGTT).

Related Videos
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Erin Michos, MD | Credit: Johns Hopkins University
Natalie McCormick, PhD | Credit: American College of Rheumatology
© 2024 MJH Life Sciences

All rights reserved.